Life Sciences

  • January 02, 2026

    Antitrust Cases Ahead: Live Nation, Middleman On Trial

    The U.S. Department of Justice and Federal Trade Commission enter 2026 with decisions to make about how to regroup after coming up short in major cases against Google and Meta Platforms.

  • January 02, 2026

    Trade Secret Trends To Watch In 2026

    The landscape of trade secret law could see significant developments in 2026 as courts address the aftermath of astronomical jury awards and navigate jurisdictional tensions surrounding the timing and specifics of trade secret disclosures in litigation.

  • January 02, 2026

    NC Legislation To Watch In 2026: Healthcare Funding In Focus

    A spate of healthcare legislation is on the line as North Carolina lawmakers get ready to return to the General Assembly in January, from tenuous funding for Medicaid and Planned Parenthood to efforts to control the Tar Heel state's skyrocketing healthcare costs.

  • January 02, 2026

    Patent Policy To Watch In 2026

    After a year of significant shifts in U.S. Patent and Trademark Office policy on patent reviews and patent eligibility, attorneys will be closely following how the changes play out in 2026, along with proposals for further moves, and whether Congress decides to weigh in on patents.

  • January 02, 2026

    California Cases To Watch In 2026

    Legal experts following California courts in 2026 are tracking high-stakes personal injury, antitrust and copyright battles against giants in the social media, artificial intelligence and entertainment industries, as well as wide-ranging legal disputes arising from Los Angeles wildfires and high-profile appeals pending before the California Supreme Court.

  • January 02, 2026

    North Carolina Cases To Watch In 2026

    In the new year, North Carolina state and federal courts are set to consider the intricacies of class action certification at the behest of thousands of fast-food workers and whether Chinese company TikTok Inc. is deliberately designing the app to addict children.

  • January 02, 2026

    New Jersey Cases To Watch In 2026

    In the coming year, New Jersey litigators will be watching for the outcome of an appeal in a constitutional challenge to school segregation and an employment discrimination case brought by a former Johnson & Johnson attorney. 

  • January 02, 2026

    What To Watch In Massachusetts Courts In 2026

    Massachusetts attorneys have their eye on Trump administration policy challenges, state ballot question disputes and False Claims Act enforcement shifts as the calendar turns to 2026.

  • January 02, 2026

    SnapChat, Pork And Big Prosecutions: Trials To Watch In 2026

    The coming year is set to bring high-profile trials, including in the criminal case against SCOTUSblog co-founder Tom Goldstein, as well as bellwether trials in multidistrict litigation concerning social media's effects on mental health and allegations of price-fixing in the generic-drug industry.

  • January 02, 2026

    Pennsylvania Cases To Watch In 2026

    As winter's chill rings in the new year, several high-profile cases are set to heat up Pennsylvania's dockets in 2026, including disciplinary charges against a judge associated with rapper Meek Mill, a pending appeals decision on the lawfulness of semiautomatic rifles, and Philadelphia's quest to hold pharmacy benefit managers accountable for the opioid epidemic.

  • January 02, 2026

    Patent Cases To Watch In 2026

    The U.S. Supreme Court is considering whether to weigh in on generic-drug skinny labels, while the Federal Circuit is examining an effort by the U.S. Patent and Trademark Office to shield decisions from review. Here's a look at those cases and others that attorneys will be tracking in 2026.

  • January 02, 2026

    The High-Stakes Healthcare AI Battles To Watch In 2026

    Courts across the country are set to hear a wave of litigation in the coming year that will begin to draw the legal boundaries around artificial intelligence in healthcare and the life sciences. Law360 spoke with legal experts about the high-stakes AI litigation set to unfold in 2026.

  • January 01, 2026

    Blue Slip Fight Looms Over Trump's 2026 Judicial Outlook

    In 2025, President Donald Trump put 20 district and six circuit judges on the federal bench. In the year ahead, a fight over home state senators' ability to block district court picks could make it more difficult for him to match that record.

  • January 01, 2026

    4 High Court Cases To Watch This Spring

    The U.S. Supreme Court justices will return from the winter holidays to tackle several constitutional disputes that range from who is entitled to birthright citizenship to whether transgender individuals are entitled to heightened levels of protection from discrimination. 

  • January 01, 2026

    BigLaw Leaders Tackle Growth, AI, Remote Work In New Year

    Rapid business growth, cultural changes caused by remote work and generative AI are creating challenges and opportunities for law firm leaders going into the New Year. Here, seven top firm leaders share what’s running through their minds as they lie awake at night.

  • December 24, 2025

    Sanofi Buys Hepatitis Vaccine Maker Dynavax For $2.2B

    French pharmaceutical giant Sanofi SA said Wednesday that it will buy Dynavax Technologies, a U.S. vaccine developer, for $2.2 billion in a recommended cash deal to expand its adult immunization products.

  • December 23, 2025

    Top Illinois Decisions Of 2025

    State and federal courts have handed down rulings in Illinois cases this year that made clear plaintiffs must allege concrete injury for common law standing, narrowed the scope of the federal anti-kickback statute and laid out a new standard for certifying collective actions.

  • December 23, 2025

    3 Federal Circuit Clashes To Watch In January

    The Federal Circuit is set to hear several intellectual property cases in January, including one over a nine-figure patent judgment against cybersecurity company Gen Digital tied to a contempt finding against a major law firm that represented it, and another over the tech industry's long-running crusade against patent review denials based on related litigation.

  • December 23, 2025

    Philly Joins MDL Against Drug Cos., PBMs Over Insulin Prices

    Philadelphia on Tuesday sued drug manufacturers Eli Lilly, Novo Nordisk and Sanofi, along with several pharmacy benefit managers, joining multidistrict litigation in New Jersey federal court accusing the companies of illegally inflating the price of insulin.

  • December 23, 2025

    Justices Urged To Spurn SG's Call To Tackle 'Skinny Labels'

    Amarin Pharma Inc. on Tuesday urged the U.S. Supreme Court to reject the U.S. solicitor general's call to hear a patent case involving generic drug "skinny labels," saying the dispute over the company's heart drug Vascepa deals with factual issues not suitable for high court review.

  • December 23, 2025

    AdaptHealth To Pay Investors $35M To End Inflated-Sales Suit

    Medical device provider AdaptHealth Corp. has agreed to pay $35 million to settle a lawsuit accusing it of deceiving shareholders about its revenue projections as it "routinely engaged in improper and unethical tactics to inflate sales numbers." 

  • December 23, 2025

    Dem Sens. Blast Idea Of Charging Value-Based Patent Fees

    A group of Democratic U.S. senators has asked Commerce Secretary Howard Lutnick not to move forward with a proposed overhaul of the U.S. patent fee system that reportedly would implement fees based on a patent's value, saying such changes would create a "prohibitive bar to innovation for start-ups and other small-to-mid-size businesses."

  • December 23, 2025

    Squires Will Review If Hydrafacial's ITC Win Should End IPR

    U.S. Patent and Trademark Office Director John Squires has paused the Patent Trial and Appeal Board's review of a Hydrafacial LLC skin treatment patent to consider the effect of a related U.S. International Trade Commission decision.

  • December 23, 2025

    Federal Agencies Urge 9th Circ. To Lift Layoff Freeze

    The U.S. government urged the Ninth Circuit to stay a court order barring agencies from laying off workers through next month under the shutdown deal, saying the court intruded on federal labor panels' territory and the funding resolution didn't bar layoffs agencies had in the works.

  • December 23, 2025

    Blue Cross Seeks McDonald Hopkins' Fraud Warning Docs

    Advice that McDonald Hopkins LLC gave a Florida hospital manager about potential exposure to criminal prosecution for healthcare fraud is neither privileged nor work product, and so should be handed over to a Blue Cross health insurer being sued for malicious prosecution in Georgia federal court, the insurer said.

Expert Analysis

  • AI Litigation Tools Can Enhance Case Assessment, Strategy

    Author Photo

    Civil litigators can use artificial intelligence tools to strengthen case assessment and aid in early strategy development, as long as they address the risks and ethical considerations that accompany these uses, say attorneys at Barnes & Thornburg.

  • Attys Beware: Generative AI Can Also Hallucinate Metadata

    Author Photo

    In addition to the well-known problem of AI-generated hallucinations in legal documents, AI tools can also hallucinate metadata — threatening the integrity of discovery, the reliability of evidence and the ability to definitively identify the provenance of electronic documents, say attorneys at Law & Forensics.

  • Lessons From Fed. Circ. On Expert Testimony In Patent Cases

    Author Photo

    Several recent decisions from the Federal Circuit are notable for their treatment of expert testimony, with relevance to the three pillars of every patent case — infringement, invalidity and damages — and offer lessons on ensuring that expert testimony is both admissible and sufficient to support the jury's verdict, say attorneys at Honigman.

  • When Atty Ethics Violations Give Rise To Causes Of Action

    Author Photo

    Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.

  • What's New In FDA's Latest Cell And Gene Therapy Guidance

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.

  • Trending At The PTAB: A Potential Barrier To Serial Challenges

    Author Photo

    New rules proposed by the U.S. Patent and Trademark Office may appear similar to previous rules at first glance, but are actually much broader in how they would limit petitioners' ability to challenge a patent more than once, say attorneys at Finnegan.

  • What's Changing For Cos. In New Calif. Hazardous Waste Plan

    Author Photo

    While the latest hazardous waste management plan from California's Department of Toxic Substances Control still awaits final approval, companies can begin aligning internal systems now with the plan's new requirements for environmental justice, waste and disposal reduction, waste criteria, and capacity planning, says Thierry Montoya at Frost Brown.

  • Fed. Circ. In September: The Printed Matter Doctrine Expands

    Author Photo

    The Federal Circuit’s recent decision in Bayer v. Mylan represents an extension of the doctrine that adding new words to an existing product or method will not support patentability unless there is a functional relationship, bringing new considerations for both patent holders and challengers, say attorneys at Knobbe Martens.

  • Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split

    Author Photo

    In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.

  • Series

    Practicing Stoicism Makes Me A Better Lawyer

    Author Photo

    Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.

  • Broader Eligibility For AI-Related Patents May Be Coming

    Author Photo

    A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick.

  • Series

    The Biz Court Digest: Texas, One Year In

    Author Photo

    A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.

  • AI Product Safety Insights May Expand Foreseeability

    Author Photo

    Product liability law has long held that companies are responsible for risks they knew about or should have known about — and with AI systems now able to assess and predict hazards during the design process, companies should expect that courts will likely treat such hazards as foreseeable, says Donald Fountain at Clark Fountain.

  • Series

    Law School's Missed Lessons: Educating Your Community

    Author Photo

    Nearly two decades prosecuting scammers and elder fraud taught me that proactively educating the public about the risks they face and the rights they possess is essential to building trust within our communities, empowering otherwise vulnerable citizens and preventing wrongdoers from gaining a foothold, says Roger Handberg at GrayRobinson.

  • Organ Transplant System Reforms Mark Regulatory Overhaul

    Author Photo

    Recent oversight, enforcement and operational developments in the U.S. organ procurement and transplantation system, alongside challenges like the federal shutdown, highlight heightened regulatory scrutiny and the need for compliance to maintain public trust, say attorneys at Hall Render.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.